Liquidia Corp's stock rose by 5.23% today, reaching a 5-day high, as the broader market showed positive momentum with the Nasdaq-100 up 0.64% and the S&P 500 up 0.47%.
This increase is attributed to Liquidia's announcement of approximately $148.3 million in YUTREPIA sales for 2025, reflecting a robust 74% quarter-over-quarter growth. The strong sales performance indicates significant market demand and the company's effective execution strategies, which have led to positive cash flow and prescription growth since the drug's launch.
The implications of this strong sales performance suggest that Liquidia is well-positioned for continued growth in the pulmonary arterial hypertension market, bolstered by its ongoing investment in clinical development and market expansion initiatives.
Wall Street analysts forecast LQDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LQDA is 47.50 USD with a low forecast of 31.00 USD and a high forecast of 67.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Analyst Rating
Wall Street analysts forecast LQDA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LQDA is 47.50 USD with a low forecast of 31.00 USD and a high forecast of 67.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
8 Buy
0 Hold
0 Sell
Strong Buy
Current: 41.910
Low
31.00
Averages
47.50
High
67.00
Current: 41.910
Low
31.00
Averages
47.50
High
67.00
H.C. Wainwright
Buy
maintain
$35 -> $50
2025-11-04
Reason
H.C. Wainwright
Price Target
$35 -> $50
AI Analysis
2025-11-04
maintain
Buy
Reason
H.C. Wainwright raised the firm's price target on Liquidia to $50 from $35 and keeps a Buy rating on the shares. The firm says the company's profitability "arrived early" with Liquidia reporting "impressive" Q3 earnings. The investment story "has shifted from a binary launch to a profit driven story," the analyst tells investors in a research note.
Raymond James
Strong Buy
maintain
$41 -> $47
2025-11-04
Reason
Raymond James
Price Target
$41 -> $47
2025-11-04
maintain
Strong Buy
Reason
Raymond James raised the firm's price target on Liquidia to $47 from $41 and keeps a Strong Buy rating on the shares. Liquidia's Q3 earnings were driven by strong Yutrepia performance in pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease, with net sales of $51.7M, over triple consensus estimates, and profitability achieved ahead of schedule, the analyst tells investors in a research note. Yutrepia accounted for roughly 75% of revenue growth in its market, aided by major PBM contracts and easing new-patient restrictions. Unadjusted peak sales estimates have been raised to about $2B from $1.1B, reflecting exceptional early launch momentum.
Unlock Full Analyst Thesis， Get the complete breakdown of rating reason for LQDA
Unlock Now
BofA
Buy
maintain
$37 -> $39
2025-11-03
Reason
BofA
Price Target
$37 -> $39
2025-11-03
maintain
Buy
Reason
BofA raised the firm's price target on Liquidia to $39 from $37 and keeps a Buy rating on the shares after the company reported Q3 net sales that beat BofA and the Street's sales forecasts. The firm believes shares are flat given the overhang on pending patent litigation that risks narrowing Yutrepia's indication statement, but it thinks today's results confirm Yutrepia's value proposition in the pulmonary hypertension market, a faster ramp to peak sales and much greater revenue opportunity from the PAH indication, the analyst tells investors.
Jefferies
Buy
maintain
$43 -> $45
2025-11-03
Reason
Jefferies
Price Target
$43 -> $45
2025-11-03
maintain
Buy
Reason
Jefferies raised the firm's price target on Liquidia to $45 from $43 and keeps a Buy rating on the shares following a strong Q3 that beat consensus and the firm's "bullish" expectations. Liquidia also hit operating profitability in Q3, two quarter's ahead of management's expectations and one quarter ahead of the firm's "already bullish estimates," the analyst added.
About LQDA
Liquidia Corporation is a biopharmaceutical company. The Company is focused on the development, manufacture and commercialization of products that address unmet patient needs, with a focus directed towards rare cardiopulmonary diseases, such as pulmonaryarterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). The Company operate through its wholly owned operating subsidiaries, Liquidia Technologies, Inc. and Liquidia PAH, LLC. Its proprietary PRINT technology is a particle engineering platform, which enable precise production of uniform drug particles. Its lead product candidate is YUTREPIA for the treatment of PAH and PH-ILD. YUTREPIA is an inhaled dry powder formulation of treprostinil designed with PRINT to improve the therapeutic profile of treprostinil by enhancing deep lung delivery while using a convenient, dry-powder inhaler (DPI) and by achieving higher dose levels than the labeled doses of current inhaled therapies.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
